BCAL’s vision is to develop and commercialise a novel blood test for the early detection of breast cancer that is safe, cost effective, accurate and available to all women regardless of age, race and geographic location. Breast cancer is the most common cancer amongst women, therefore, the effectiveness of the screening and diagnosis technology used is a high priority.
The current model relies on a woman having to be physically present at a clinic for breast imaging. This is not always ideal as clinics are not readily accessible, and it is not necessarily convenient for the visiting patient. Many women are also not very comfortable with the process of breast imaging which can involve multiple technologies. While the present technologies are currently state of the art, there is a high cost involved, and well-known performance limitations that result in only a small subset of women who are actually eligible for screening.
BCAL Diagnostics aims to shift the paradigm in breast cancer screening and diagnosis by introducing a blood test for detection of the disease. The implication of such a technology could revolutionise the way we identity and manage breast cancer by allowing a blood sample to be taken remote from the site of analysis. This means that the technology will allow access to more women, anywhere in the world, who could provide a blood sample, at a time and place of their convenience. Such a test would fit into a woman's routine health regime and be incorporated into their personal lifestyle.
In addition, with such high levels of accuracy, this technology would provide greater peace of mind, for a woman, between annual checks.